Related Experiment Videos

[Ketamine lollipop for pediatric premedication]

T Horiuchi1, K Kurehara, K Kitaguchi

  • 1Department of Anesthesiology, Nara Medical University, Kashihara 634-8521.

Masui. the Japanese Journal of Anesthesiology
|May 11, 2001
PubMed

Insights

Ketamine lollipop (50 mg) shows promise for pediatric premedication, maintaining good emotional states and avoiding side effects in young patients. This novel formulation offers a potentially effective and well-tolerated option for children undergoing medical procedures.

Area of Science:

  • Anesthesiology
  • Pediatric Medicine
  • Pharmacology

Context:

  • Premedication in pediatric patients is crucial for managing anxiety and ensuring cooperation during medical procedures.
  • Traditional premedication methods can have drawbacks, necessitating the exploration of novel delivery systems.
  • Ketamine is an anesthetic agent with sedative and anxiolytic properties.

Purpose:

  • To evaluate the efficacy and safety of a 50 mg ketamine lollipop as a premedication agent in pediatric patients.
  • To assess the emotional state and presence of side effects in children receiving ketamine lollipop premedication.
  • To determine the potential of ketamine lollipop as a viable alternative for pediatric premedication.

Summary:

  • A study involving 12 pediatric patients (aged 1 year 7 months to 6 years) administered a 50 mg ketamine lollipop for premedication.
  • Patients exhibited a generally good emotional state post-administration.
  • No typical adverse side effects associated with ketamine were observed in the study group.

Impact:

  • The ketamine lollipop formulation demonstrates a favorable safety profile and tolerability in young children.
  • Results suggest that ketamine lollipop is a promising option for premedication in pediatric settings.
  • This novel delivery method could improve the patient experience and procedural outcomes for pediatric medical interventions.

Related Concept Videos